Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis | Zendy

An S. De Vriese | Zendy; Rudy Van Coster | Zendy; Joél Smet | Zendy; Sara Seneca | Zendy; A. M. Lovering | Zendy; Lindsey Van Haute | Zendy; Ludo Vanopdenbosch | Zendy; JeanJacques Martin | Zendy; Chantal Ceuterickde Groote | Zendy; Stefaan J. Vandecasteele | Zendy; Johan R. Boelaert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Linezolid-Induced Inhibition of Mitochondrial Protein Synthesis

Author(s) -

An S. De Vriese,

Rudy Van Coster,

Joél Smet,

Sara Seneca,

A. M. Lovering,

Lindsey Van Haute,

Ludo Vanopdenbosch,

JeanJacques Martin,

Chantal Ceuterickde Groote,

Stefaan J. Vandecasteele,

Johan R. Boelaert

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/501356

Subject(s) - linezolid , medicine , mitochondrion , microbiology and biotechnology , bacteria , biochemistry , staphylococcus aureus , genetics , biology , vancomycin

Linezolid is an oxazolidinone antibiotic that is increasingly used to treat drug-resistant, gram-positive pathogens. The mechanism of action is inhibition of bacterial protein synthesis. Optic and/or peripheral neuropathy and lactic acidosis are reported side effects, but the underlying pathophysiological mechanism has not been unravelled.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research